Cardiovascular Risk, Diabetes
Read Time: 5 mins

Skin Autofluorescence – A Non-invasive Measurement for Assessing Cardiovascular Risk and Risk of Diabetes

Copy Link
Published Online: May 27th 2014 European Endocrinology, 2014;10(2):106–10 DOI:
Authors: Alin Stirban, Lutz Heinemann
Quick Links:
Article Information

The results of the Diabetes Control and Complications Trial-Epidemiology of Diabetes Interventions and Complications (DCCT-EDIC) study have strengthened the ‘glycaemic memory’ concept, postulating that the quality of metabolic control over several years predicts the development of diabetic complications. To mirror long-term metabolic control, the degree of glycated haemoglobin (HbA1c) might not represent the optimal biomarker. Other substances with a longer persistence, like the so-called advanced glycation end-products (AGEs), which probably form the substrate of the glycaemic memory, might perform better. Newly developed methods such as the assessment of skin autofluorescence (SAF), enable fast, uncomplicated and non-invasive AGEs assessment. SAF was validated for diabetes screening and shows a good predictive value for the development of diabetic and cardiovascular complications. This article deals with the theoretical background and with available clinical data on this new variable.


Advanced glycation end-products, skin autofluorescence, cardiovascular risk, diabetes, complications


Theoretical Background

Theoretical Background
Advanced glycation end-products (AGEs) and oxidative stress (OS) are two main contributors to the development of diabetic complications.1,2 AGEs represent a heterogeneous substance class, produced through nonenzymatic glycation of proteins, lipids or nucleic acids within the so-called Maillard reaction (MR). Intermediate products of the MR are Schiff’s bases and Amadori products (e.g. the glycated haemoglobin [ HbA1c]).3 The MR is important for nutrient preparation, explaining the browning of foods during heating causing specific colour and taste. Food AGEs are partially absorbed from the gut,4 but AGEs are also produced endogenously under physiological conditions. This process is exacerbated by hyperglycaemia, hyperlipidaemia or increased OS.3

Endogenous and exogenous AGEs are partially degraded in the body or eliminated via the kidneys. Modification of the aminoacid(s) in the active centre of the enzyme by the AGEs is responsible, for example, for the alterations of enzyme activity (non-receptor-dependent mechanisms). In addition, AGEs bind to specific receptors thus inducing intracellular processes such as OS or inflammation (receptor-dependent mechanisms). An increased endogenous and exogenous AGEs supply and accumulation contributes to the development of vascular complications in both patients with and without diabetes,3 thus playing a central role in the ‘glycaemic memory’ concept.

The Diabetes Control and Complications Trial (DCCT) demonstrated that improved metabolic control in patients with type 1 diabetes mellitus (T1DM) reduces microvascular and neuropathic complications.5 The fact that glycated proteins form stable AGEs, which accumulate in tissues affected by diabetes complications6 led to the establishment of the previously mentioned concept of glycaemic memory.7 The assumption is that AGEs represent the substrate of the glycaemic memory and cause diabetes complications.8 Measuring AGEs might therefore represent an integrated variable, reflecting tissue glucose exposure over several years and thus more accurately predicting the risk of diabetes complications than the HbA1c that mirrors glycaemic control over 8–12 weeks only.8,9

Circulating or tissue-bound AGEs can be measured using enzymelinked immunosorbent assay (ELISA), fluorescence spectroscopy, fluid chromatography and gas chromatography with mass spectrometry.10 While the measurement of circulating AGEs shows high physiological fluctuations (e.g. postprandial),4 the measurement of tissue-bound AGEs is more stable. In particular, tissues with a slow turnover (e.g. dermis, vascular walls and eye lenses) display a high AGEs accumulation and are therefore most suitable for AGEs assessment.11

The skin represents the most accessible tissue for AGEs measurements, with the biochemical analysis of skin biopsies constituting the golden standard.11,12 However, this method is invasive, expensive, requires analysis in specialised centres and results are available within days to weeks. A growing interest in the non-invasive assessment of AGEs existed lately and non-invasive methods were developed which measure the AGEs-related EUROPEAN ENDOCRINOLOGY 107 autofluorescence (AF) of the skin (AGE Reader, DiagnOptics, Groningen, the Netherlands, or SCOUT DS®, VeraLight, Albuquerque, New Mexico, USA), of the cornea or the lens (FluorotronTM, OcuMetrics, Mountain View, California, USA), allowing for a quick, reproducible and relatively low-cost measurement of AGEs accumulation.12–14 Interestingly, not all devices were developed from the very beginning with the purpose of measuring AGErelated fluorescence. The Fluorotron device primary purpose, for example, was to assess the retinal leakage by measuring fluorescein fluorescence (the excitation light it emits is of 440–480 nm and detector is capturing 531–634 nm, fluorescein ex/em of 490/520 nm) in the eye after intravenous injection. However, the instrument was demonstrated to be useful in the assessment of eye-related AGEs-like fluorescence.

Measurement of the Skin Autofluorescence
The AF represents the natural light emission of substrates, after they have absorbed light.12 The spectroscopic measurements of AGEs in the skin are based on the autofluorescent properties of some (e.g. pentosidine) but not of all (e.g. carboxymethyllysine) AGEs.15 In addition, some redox regulated fluorophores (such as nicotine amide adenine dinucleotide reduced [NADH], flavin-adenine-dinucleotide [FAD] and porphyrins) display AF.16,17 However, about 76 % of the variability of the SAF can be explained by the variability of pentosidine (a major AGE) concentration in the skin.18 It is worth mentioning that fluorescence properties of pentosidine are: excitation 325–335 nm and emission 375 385 nm. Thus the AGE Reader is targeting only part of the pentosidine fluorescence spectrum.

Overall, Skin Autofluorescence is Regarded as a Surrogate Variable of Skin Advanced Glycation End-product Accumulation
The AGE Reader (DiagnOptics) non-invasively assesses SAF. Subjects lay their arm on a special arm rest with a window in the middle (see Figure 1). A skin surface of around 4 cm2, guarded against surrounded light is illuminated with an excitation light source consisting of multiple lightemitting diodes (LEDs) with various intensities (maximum intensity at a wave length of approximately 370 nm) in a frequency range of 300 to 420 nm. The autofluorescent light is captured by multiple photo diodes, analysed and SAF is expressed in arbitrary units (AUs). The resultant SAF is calculated as the ratio of the light intensity in the 420–600 nm wavelength range and the light intensity in the 300–420 nm wavelength range. Further technical details were published by Meerwaldt et al.19 Results are displayed within seconds, together with age-corrected reference values.

SAF measurements were validated against results of biochemical analyses of skin biopsies in healthy subjects, subjects with type 1 or type 2 diabetes mellitus (T2DM) and normal renal function,12 as well as in subjects on haemodialysis.18,20 AGEs accumulate in a comparable manner within various organs, and for SAF measurement the sun exposure seems not to be a major confounder. Indeed, SAF measured at the forehead (sun-exposed skin) and at the buttocks correlate well.16 SAF correlates with the corneal and the lens AF21 as well as with the AGEs concentration in material from bypass surgery.22

In persons with diabetes, SAF has an intra-individual, intra-day variability of 4.2–5.0 % and a seasonal variability of 5.9 %.9,12,23 Our own study reported an intra-individual variability of 6.9 % and 10.9 % at 6 and 12 weeks, respectively.24 A modest postprandial increase in SAF was described in some,25,26 but not in all,23 studies – a fasting measurement is therefore not mandatory.

The SAF shows a linear increase of 0.023 AU/year for persons up to 70 years.27 Further important contributors to SAF are: smoking status, skin tone, renal function and average HbA1c value.9 For measurements with the AGE Reader reference values exist for Caucasians15,27 (see Table 1) and Asians.28 Klenovics et al.29 recently reported slight differences in SAF in a Slovakian population compared with a Dutch population suggesting that for precise clinical interpretation specific population-derived reference data should be obtained. The same study group suggested that persons exerting increased physical activity show lower SAF values.

In patients with T1DM, the age-adjusted SAF correlates significantly with the long-term HbA1c (ca. 15 years) but not with the current HbA1c.30,31 Therefore, due to their long persistence, AGEs assessment might be superior to the measurement of HbA1c with regard to the prediction of diabetes risk, the risk of development of cardiovascular and diabetes complications and mortality.

There are several drawbacks of SAF measurements, such as the impossibility to use SAF in persons with a very dark skin and the possibility that some external factors (e.g. creams, sunscreens, self-browning creams, extreme hyperaemia or vasoconstriction, etc.) can influence SAF measurements as reported by Noordzij et al.32

Skin Autofluorescence for the Diagnosis of Diabetes Mellitus
Fasting plasma glucose (FPG), glucose excursions during an oral glucose tolerance test (OGTT) and the HbA1c are established biomarkers for diabetes diagnosis, but have some drawbacks: high costs, time consumption or limited sensitivity.33 Since the development of type 2 diabetes is preceded by years of subclinical metabolic disturbances potentially leading to AGEs accumulation, it is conceivable that skin AGEs might be used for diabetes screening. In a study including 218 persons with a medium diabetes risk, SAF measurement combined with an algorithm to diagnose diabetes (SAF-DM, see Figure 2), was superior to FPG and not inferior to HbA1c (sensitivity 82 %; specificity 89 %).34 In two further studies, SAF displayed a higher sensitivity than FPG or HbA1c for diagnosing diabetes.35,36 Nevertheless, the usage of SAF in the diagnosis of diabetes mellitus is highly controversial and taking into account the kidney function is paramount for an accurate interpretation of results.

Skin Autofluorescence and Diabetes Complications
In patients with T2DM (n=973) compared with 231 healthy, higher SAF in nearly all age categories was reported (see Table 1).15 In patients with diabetes and microvascular and macrovascular complications, SAF was higher (mean: 3.12 AU) than in those with microvascular complications only (2.71 AU), or patients without complications (2.57 AU; p<0.001 for all). Even in patients with macrovascular complications only, SAF was higher (2.91 AU) than in those without complications. Similar results yield a study by Noordzij et al.37

In n=881 persons with T2DM and good metabolic control (mean HbA1c 6.6 %) observed on average for 3.1 years, SAF demonstrated a good predictive value (odds ratio [OR] 2.05; p>0.001) for the development of microvascular complications, in particular for neuropathy and nephropathy, but not for retinopathy.38 The predicative value of SAF was higher than that of HbA1c and diabetes duration. These results were confirmed by another study in T1DM persons in whom an association of SAF with nephropathy or neuropathy was found, but not with retinopathy.39 Sugisawa demonstrated a significant association between SAF and diabetic neuropathy and retinopathy.31 In patients with T1DM, SAF was higher in those with peripheral (PNP) and autonomic (ANP) neuropathy (p<0.0001 for both); and each SAF increase by a standard deviation was associated with a 2.6 times higher probability of ANP.40 Furthermore, Meerwaldt and colleagues demonstrated that SAF increases with the severity of ANP and PNP even at subclinical stages.41

Skin Autofluorescence, Cardiovascular Risk and Mortality
SAF correlates with both early vascular changes (e.g. vascular stiffness [VS], intima-media thickness [IMT] and overt atherosclerosis). AGEs contribute to the development of VS (a predictor for total as well as cardiovascular mortality).42,43 SAF correlated with the VS in healthy (especially younger) persons,44,45 in patients with T1DM21 as well as in persons who underwent coronary bypass surgery.22 A correlation of SAF with the IMT of the carotid artery (an established cardiovascular risk marker46) was found in healthy non-smokers.47

SAF was elevated (2.66 AU) in subjects with carotid artery stenosis and further increased (3.28 AU) with the additional presence of peripheral artery disease (PAD).48 Conversely, SAF was increased in people with PAD versus without PAD (2.77 versus 2.44 AU; p<0.001).49 The adjusted OR for the presence of PAD was 2.47 per unit elevation of SAF. In 252 PAD patients, SAF was independently associated with all-cause mortality and fatal or non-fatal major adverse cardiovascular events within 5 years.50

In patients with T1DM, SAF was associated with the calcification of coronary arteries51 and was higher in persons with overt coronary heart disease (CHD) (p<0.0001), correlating significantly with the CHD (OR 3.5).13 For patients with T2DM, Lutgers et al.52 reported that adding SAF to the United Kingdom Prospective Diabetes Study (UKPDS) risk score calculation improves risk stratification in both low- and high-risk groups.

In patients with diabetes (n=48 with type 1; n=69 with type 2) and healthy (n=43) observed over 5 years, SAF was strongly associated with CHD (OR 7.9) and mortality (OR 2.0).53 Increased mortality in both T1DM and T2DM occurred when SAF exceeded 2.0 AU and further increased when SAF >3.0 AU. SAF was more strongly associated with CHD and mortality than HbA1c, triglycerides or low-density lipoprotein (LDL) cholesterol. This underlines the remarkable predicative value of SAF in patients at risk.

SAF was elevated in subjects with stable CHD compared with healthy54 people and it seems to further increase during an acute event like STelevation myocardial infarction (probably due to exacerbated OS and inflammation) and decreases after the acute event (>200 days).55 An SAF value above the median was predictive of further cardiovascular events (hazard ratio [HR] –HR 11.6), an important aspect for risk stratification.

Skin Autofluorescence and Chronic Kidney Disease
Elevated serum AGEs concentrations in persons with CKD are due to exacerbated OS, which accompanies uraemia, dyslipidaemia,56 elevated AGEs production57,58 and reduced AGEs renal clearance. For example, up to 30 % of exogenous AGEs are eliminated renally – this amount decreases to 5 % when CKD occurs. It is therefore conceivable that patients with CKD stage 3,60 terminal CKD or persons undergoing dialysis displayed higher SAF.44,61 At the same time, SAF was found to be a strong and independent predictor of CKD progression.62

Renal transplantation reduces but does not normalise SAF, an effect dependent on the functional quality of the transplant63 but probably also on the accompanying medication.64 Another study in 302 renal transplant patients showed that elevated SAF was associated with a HR of 2.40 for transplant loss within 5.2 years (p<0.01).65 Therefore, SAF was proposed to be used for the identification and monitoring of patients at risk of renal transplant dysfunction as well as of cardiovascular complications.66

In dialysis patients, SAF strongly predicts mortality within 3 years,20 with a higher OR for the overall mortality than a pre-existing cardiovascular disease (OR 3.9 versus 3.1) and an OR of 6.8 for cardiovascular mortality. In line with this, Kimura et al. demonstrated in 128 patients on chronic haemodialysis observed over 6 years that SAF represents an independent predictor of cardiovascular mortality (adjusted HR 3.97).67 Another study also found SAF to be an independent predictor of overall mortality (HR 1.83) but not of cardiovascular mortality.68

AGEs appear to play a major role in the development of diabetic and cardiovascular complications. Non-invasive SAF measurements allow for a quantification of the AGEs load and show a good predictive value (better than the HbA1c) for the development of diabetic complications, microvascular and macrovascular disease, cardiovascular and overall mortality.

As mentioned, some limitations of SAF measurements are related to very dark skin and the influence of some external factors (creams, extreme vasoconstriction or vasodilatation, etc.) Furthermore, the validity of measurements in terms of diabetic and cardiovascular complications depends maybe not only on renal function but also on dietary factors like AGEs intake. Indeed, intake of dietary AGEs significantly increases circulating AGEs69,70 and influences SAF in infants.29 In adults, acute consumption of dietary AGEs with a meal inconsistently and only minimally increases SAF, therefore we discussed that it is not necessary to measure SAF in fasting state.25,24 However, to our knowledge, evidence of effects of long-term dietary AGEs intake on SAF in adults are lacking.

Some reports suggest that SAF measurement constitutes a variable suitable for large-scale diabetes screening, but these data are controversial. Overall, further studies are warranted to strengthen the role of SAF measurements in clinical routine.

Article Information:

Alin Stirban and Lutz Heinemann have received fees from DiagnOptics.


Alin Stirban, Director Endocrinology and Diabetes Complications, Institut für Stoffwechselforschung GmbH, Hellersbergstr. 9, 41460 Neuss, Germany. E:


The publication of this article was supported by DiagnOptics. The views and opinions expressed are those of the authors and not necessarily those of DiagnOptics.




  1. Vlassara H, Uribarri J, Glycoxidation and diabetic complications: modern lessons and a warning?, Rev Endocr Metab Disord, 2004;5:181–8.
  2. Vlassara H, Striker G, The role of AGE-products in the etiology of insulin resistance and diabetes, US Endocrinology, 2010;6:14–9.
  3. Vlassara H, Advanced glycation in health and disease: role of the modern environment, Ann N Y Acad Sci, 2005;1043:452–60.
  4. Stirban A, Negrean M, Stratmann B, et al., Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes, Diabetes Care, 2006;29:2064–71.
  5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group, N Engl J Med, 1993;329:977–86.
  6. Vlassara H, Bucala R, Striker L, Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging, Lab Invest, 1994;70:138–51.
  7. Pop-Busui R, Herman WH, Feldman EL, et al., DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history, Curr Diab Rep, 2010;10:276–82.
  8. Monnier VM, Bautista O, Kenny D, et al., Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with longterm intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial, Diabetes, 1999;48:870–80.
  9. Cleary P, Braffett B, Orchard T, et al., and the DCCT/EDIC Research Group, Clinical and Technical Factors Associated with Skin Intrinsic Fluorescence in Subjects with Type 1 Diabetes from the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Study, Diabetes Technology & Therapeutics, 2013;15:466–74.
  10. Mulder DJ, Water TV, Lutgers HL, et al., Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations, Diabetes Technol Ther, 2006;8:523–35.
  11. Lyons TJ, Bailie KE, Dyer DG, Dunn JA, Baynes JW, Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus, J Clin Invest, 1991;87:1910–5.
  12. Meerwaldt R, Graaff R, Oomen PH, et al., Simple non-invasive assessment of advanced glycation endproduct accumulation, Diabetologia, 2004;47:1324–30.
  13. Conway BN, Aroda VR, Maynard JD, et al., Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes, Diabetes Care, 2012;35:2331–6.
  14. Kessel L, Hougaard JL, Sander B, et al., Lens ageing as an indicator of tissue damage associated with smoking and non-enzymatic glycation – a twin study, Diabetologia, 2002;45:1457–62.
  15. Lutgers HL, Graaff R, Links TP, et al., Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes, Diabetes Care, 2006; 29:2654–59.
  16. Na R, Stender IM, Ma L, Wulf HC, Autofluorescence spectrum of skin: component bands and body site variations, Skin Res Technol, 2000; 6:112–7.
  17. Sell DR, Nemet I, Monnier VM, Partial characterization of the molecular nature of collagen-linked fluorescence: role of diabetes and end-stage renal disease, Arch Biochem Biophys, 2010;493:192–206.
  18. Smit AJ, Gerrits EG, Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease, Curr Opin Nephrol Hypertens, 2010;19:527–33.
  19. Meerwaldt R, Links T, Graaff R, et al., Simple noninvasive measurement of skin autofluorescence, Ann N Y Acad Sci, 2005;1043:290–8.
  20. Meerwaldt R, Hartog JW, Graaff R, et al., Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients, J Am Soc Nephrol, 2005;16:3687–93.
  21. Januszewski AS, Sachithanandan N, Karschimkus C, et al., Non-invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction, Diabet Med, 2012;29:726–33.
  22. Hofmann B, Adam AC, Jacobs K, et al., Advanced glycation end product associated skin autofluorescence: a mirror of vascular function?, Exp Gerontol, 2013;48:38–44.
  23. de Ranitz-Greven WL, Kaasenbrood L, Poucki WK, et al., Advanced glycation end products, measured as skin autofluorescence, during normal pregnancy and pregnancy complicated by diabetes mellitus, Diabetes Technol Ther, 2012;14:1134–9.
  24. Stirban A, Pop A, Fischer A, et al., Variability of skin autofluorescence measurement over 6 and 12 weeks and the influence of benfotiamine treatment, Diabetes Technol Ther, 2013; 15:733–7.
  25. Stirban S, Nandrean S, Negrean M, et al., Skin autofluorescence increases postprandially in human subjects, Diabetes Technol Ther, 2008;10:200–5.
  26. Noordzij MJ, Lefrandt JD, Graaff R, Smit AJ, Skin autofluorescence and glycemic variability, Diabetes Technol Ther, 2010;12:581–5.
  27. Koetsier M, Lutgers HL, de Jonge C, et al., Reference values of skin autofluorescence, Diabetes Technol Ther, 2010;12:399–403.
  28. Yue X, Hu H, Koetsier M, et al., Reference values for the Chinese population of skin autofluorescence as a marker of advanced glycation end products accumulated in tissue, Diabet Med, 2011;28:818–23.
  29. Klenovics KS, KRHJCPSK, Reference values of skin autofluorescence as an estimation of tissue accumulation of advanced glycation end products in a general Slovak population, Diabetic Med, 2014; 31:581–5.
  30. Aroda VR, Conway BN, Fernandez SJ, et al., Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetes, Diabetes Technol Ther, 2013;15:117–23.
  31. Sugisawa E, Miura J, Iwamoto Y, Uchigata Y, Skin autofluorescence reflects integration of past long-term glycemic control in patients with type 1 diabetes, Diabetes Care, 2013;36:2339–45.
  32. Noordzij MJ, Lefrandt JD, Graaff R, Smit AJ, Dermal factors influencing measurement of skin autofluorescence, Diabetes Technol Ther, 2011;13:165–70.
  33. Standards of medical care in diabetes – 2013, Diabetes Care, 2013;36 Suppl. 1:S11–66.
  34. Smit AJ, Smit JM, Botterblom GJ, Mulder DJ, Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes, PLoS One, 2013; 8:e65592-
  35. Maynard JD, Rohrscheib M, Way JF, et al., Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C, Diabetes Care, 2007;30:1120–4.
  36. Tentolouris N, Lathouris P, Lontou S, et al., Screening for HbA1c-defined prediabetes and diabetes in an at-risk greek population: Performance comparison of random capillary glucose, the ADA diabetes risk test and skin fluorescence spectroscopy, Diabetes Res Clin Pract, 2013;100:39–45.
  37. Noordzij MJ, Mulder DJ, Oomen PH, et al., Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study, Diabet Med, 2012;29:1556–61.
  38. Gerrits EG, Lutgers HL, Kleefstra N, et al., Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications, Diabetes Care, 2008;31:517–21.
  39. Chabroux S, Canoui-Poitrine F, Reffet S, et al., Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy, Diabetes Metab, 2010;36:152–7.
  40. Conway BN, Aroda VR, Maynard JD, et al., Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes, Diabetes Care, 2011;34:1000–5.
  41. Meerwaldt R, Links TP, Graaff R, et al., Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy, Diabetologia, 2005;48:1637–44.
  42. Kitahara T, Ono K, Tsuchida A, et al., Impact of brachial-ankle pulse wave velocity and ankle-brachial blood pressure index on mortality in hemodialysis patients, Am J Kidney Dis, 2005;46:688–96.
  43. Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ, The role of glycation cross-links in diabetic vascular stiffening, Diabetologia, 1996;39:946–51.
  44. Ueno H, Koyama H, Tanaka S, et al., Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease, Metabolism, 2008;57:1452–7.
  45. Watfa G, Soulis G, Tartagni E, et al., Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly non-diabetic populations, Diabetes Metab, 2012;38:413–9.
  46. van den Oord SC, Sijbrands EJ, Ten Kate GL, et al., Carotid intima-media thickness for cardiovascular risk assessment: Systematic review and meta-analysis, Atherosclerosis, 2013;228:1–11.
  47. Lutgers HL, Graaff R, de Vries R, et al., Carotid artery intima media thickness associates with skin autofluoresence in nondiabetic subjects without clinically manifest cardiovascular disease, Eur J Clin Invest, 2010; 40:812–7.
  48. Noordzij MJ, Lefrandt JD, Loeffen EA, et al., Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease, Int J Cardiovasc Imaging, 2012;28:431–8.
  49. de Vos LC, Noordzij MJ, Mulder DJ, et al., Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease, Arterioscler Thromb Vasc Biol, 2013;33:131–8.
  50. de Vos LC, Mulder DJ, Smit AJ, et al., Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease, Arteriosclerosis, Thrombosis, and Vascular Biology, 2014;34:933–8.
  51. Conway B, Edmundowicz D, Matter N, et al., Skin fluorescence correlates strongly with coronary artery calcification severity in type 1 diabetes, Diabetes Technol Ther, 2010;12:339–45.
  52. Lutgers HL, Gerrits EG, Graaff R, et al., Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus, Diabetologia, 2009;52:789–97.
  53. Meerwaldt R, Lutgers HL, Links TP, et al., Skin autofluorescence is a strong predictor of cardiac mortality in diabetes, Diabetes Care, 2007;30:107–12.
  54. Mulder DJ, van Haelst PL, Gross S, et al., Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products, Atherosclerosis, 2008;197:217–23.
  55. Mulder DJ, van Haelst PL, Graaff R, et al., Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events, Neth Heart J, 2009;17:162–8.
  56. Baynes JW, Thorpe SR, Glycoxidation and lipoxidation in atherogenesis, Free Radic Biol Med, 2000; 28:1708–16.
  57. Weiss MF, Erhard P, Kader-Attia FA, et al., Mechanisms for the formation of glycoxidation products in end-stage renal disease, Kidney Int, 2000;57:2571–85.
  58. Uribarri J, Peppa M, Cai W, et al., Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients, J Am Soc Nephrol, 2003;14:728–31.
  59. Koschinsky T, He CJ, Mitsuhashi T, et al., Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy, Proc Natl Acad Sci U S A, 1997;94:6474–9.
  60. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW, Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3, Clin J Am Soc Nephrol, 2011;6:2356–63.
  61. McIntyre NJ, Chesterton LJ, John SG, et al., Tissue-advanced glycation end product concentration in dialysis patients, Clin J Am Soc Nephrol, 2010;5:51–5.
  62. Tanaka K, Nakayama M, Kanno M, et al., Skin autofluorescence is associated with the progression of chronic kidney disease: a prospective observational study, PLoS One, 2013;8:e83799.
  63. Hartog JW, de Vries AP, Lutgers HL, et al., Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease, Ann N Y Acad Sci, 2005;1043:299–307.
  64. Sebekova K, Podracka L, Heidland A, Schinzel R, Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation--are they inter-related?, Clin Nephrol, 2001;56:S21–6.
  65. Hartog JW, Gross S, Oterdoom LH, et al., Skin-autofluorescence is an independent predictor of graft loss in renal transplant recipients, Transplantation, 2009;87:1069–77.
  66. Hartog JW, de Vries AP, Bakker SJ, et al., Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients, Nephrol Dial Transplant, 2006;21:2263–9.
  67. Kimura H, Tanaka K, Kanno M, et al., Skin autofluorescence predicts cardiovascular mortality in patients on chronic hemodialysis, Ther Apher Dial, 2014; [Epub ahead of print].
  68. Gerrits EG, Lutgers HL, Smeets GH, et al., Skin autofluorescence: a pronounced marker of mortality in hemodialysis patients, Nephron Extra, 2012;2:184–91.
  69. Birlouez-Aragon I, Saavedra G, Tessier FJ, et al., A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases, Am J Clin Nutr, 2010;91:1220–6.
  70. Cai W, He JC, Zhu L, et al., High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients, Circulation, 2004;110:285–91.

Further Resources

Share this Article
Related Content In Diabetes
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72